- Home
- FLNG vs ELVN Comparison
FLNG vs ELVN Comparison
Compare FLNG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- ELVN
- Stock Information
- Founded
- FLNG 2006
- ELVN 2016
- Country
- FLNG Bermuda
- ELVN United States
- Employees
- FLNG N/A
- ELVN N/A
- Industry
- FLNG Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- FLNG Consumer Discretionary
- ELVN Health Care
- Exchange
- FLNG Nasdaq
- ELVN Nasdaq
- Market Cap
- FLNG 1.3B
- ELVN 927.8M
- IPO Year
- FLNG N/A
- ELVN 2020
- Fundamental
- Price
- FLNG $21.88
- ELVN $19.65
- Analyst Decision
- FLNG Hold
- ELVN Strong Buy
- Analyst Count
- FLNG 1
- ELVN 5
- Target Price
- FLNG $23.00
- ELVN $39.60
- AVG Volume (30 Days)
- FLNG 443.8K
- ELVN 715.5K
- Earning Date
- FLNG 08-13-2025
- ELVN 08-12-2025
- Dividend Yield
- FLNG 13.71%
- ELVN N/A
- EPS Growth
- FLNG N/A
- ELVN N/A
- EPS
- FLNG 1.91
- ELVN N/A
- Revenue
- FLNG $354,551,000.00
- ELVN N/A
- Revenue This Year
- FLNG N/A
- ELVN N/A
- Revenue Next Year
- FLNG $3.64
- ELVN N/A
- P/E Ratio
- FLNG $11.51
- ELVN N/A
- Revenue Growth
- FLNG N/A
- ELVN N/A
- 52 Week Low
- FLNG $19.46
- ELVN $13.30
- 52 Week High
- FLNG $27.77
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- FLNG 28.29
- ELVN 46.72
- Support Level
- FLNG $23.69
- ELVN $20.22
- Resistance Level
- FLNG $24.68
- ELVN $21.90
- Average True Range (ATR)
- FLNG 0.60
- ELVN 1.55
- MACD
- FLNG -0.27
- ELVN -0.24
- Stochastic Oscillator
- FLNG 4.51
- ELVN 20.07
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.